Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568246 | 0.94 | PDK1 (0.38) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL4568245 | 0.88 | HDAC1 (0.41) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL23885268 | 0.86 | CA2 (0.41) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL30254633 | 0.86 | CA2 (0.41) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL23885594 | 0.85 | NPC1 (0.42) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL30254505 | 0.85 | NPC1 (0.42) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL4568240 | 0.83 | SMN1; SMN2 (0.41) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL4568248 | 0.83 | PDK1 (0.40) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL24170460 | 0.81 | CA1 (0.45) | MEN1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL31648042 | 0.81 | CA2 (0.46) | PDK1PDK2PDK3PDK4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115427044-A | Pyrrolopyrimidines as complement inhibitors | 拜奥克里斯特制药公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021202977-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | PDK1 4256/4885PDK2 2782/4885PDK3 2580/4885 |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | PDK1 723/4885PDK2 796/4885PDK3 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.